US 12,186,275 B2
Enhancing the effect of CAR-engineered T cells by means of nucleic acid vaccination
Ugur Sahin, Mainz (DE); Katharina Reinhard, Mainz-Kostheim (DE); Petra Simon, Mainz (DE); Karolina Anna Mroz, Wiesbaden (DE); and Kathleen Hobohm, Kelkheim i. Ts. (DE)
Assigned to BioNTach Ceil & Gene Therapies GmbH and TRON—Translationaie Onkologie an der Universitaismedizin der Johannes Gutenberg-univer, Mainz (DE)
Filed by BioNTech Cell & Gene Therapies GmbH, Mainz (DE); and TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz GGMBH, Mainz (DE)
Filed on Aug. 7, 2020, as Appl. No. 16/988,117.
Application 16/988,117 is a continuation of application No. 15/573,045, granted, now 10,799,534, previously published as PCT/EP2016/060332, filed on May 9, 2016.
Claims priority of application No. PCT/EP2015/060356 (WO), filed on May 11, 2015.
Prior Publication US 2020/0360438 A1, Nov. 19, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 9/127 (2006.01); A61K 35/17 (2015.01); A61K 39/395 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01)
CPC A61K 39/0011 (2013.01) [A61K 9/127 (2013.01); A61K 35/17 (2013.01); A61K 39/001102 (2018.08); A61K 39/00111 (2018.08); A61K 39/001112 (2018.08); A61K 39/001113 (2018.08); A61K 39/001124 (2018.08); A61K 39/001168 (2018.08); A61K 39/001182 (2018.08); A61K 39/001188 (2018.08); A61K 39/001195 (2018.08); A61K 39/39558 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464402 (2023.05); A61K 39/464412 (2023.05); C07K 14/7051 (2013.01); C07K 16/28 (2013.01); C12N 5/0636 (2013.01); A61K 2039/53 (2013.01); A61K 2239/17 (2023.05); A61K 2239/22 (2023.05); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); A61K 2300/00 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01)] 29 Claims
 
1. A method for stimulating an immune response to a target cell population or target tissue expressing an antigen in a mammal, the method comprising:
(a) transfecting a T cell of the mammal with a first nucleic acid encoding a chimeric antigen receptor (CAR) targeted to the antigen, wherein transfecting the T cell is in vivo; and
(b) administering a second nucleic acid encoding the antigen or a variant thereof, wherein the second nucleic acid is in vitro transcribed RNA disposed in liposomes, in a pharmaceutically acceptable carrier, diluent, buffer, preservative, or excipient.